Wu NL, Phipps AI, Krull KR, et al. Long-Term Patient-Reported Neurocognitive Outcomes in Adult Survivors of Hematopoietic Cell Transplant. Blood Advances. 2022; (doi: 10.1182/bloodadvances.2021006672).
Adult survivors of hematopoietic cell transplant (HCT) tended to rate their post-transplant neurocognitive quality of life as average compared with the general population, while those with hearing and sleep problems were more likely to report reduced quality of life and impaired neurocognitive ability, according to new research. Qualifying survivors (age ≥21 years at HCT and alive ≥2 years post-HCT) responded to a poll that included the Neuro-Quality of Life Cognitive Function Short Form (Neuro-QoL) and the Childhood Cancer Survivor Study Neurocognitive Questionnaire (NCQ). In all, 1,861 survivors (47.7% women and 65.6% allogeneic HCT survivors) were surveyed at a median age of 64.2 years and a median 12 years after HCT. Survivors' Neuro-QoL scores were average (50.0 for allogeneic and 49.2 for autologous survivors) compared with an expected mean of 50 in the general population. For the NCQ, 17.4%-31.2% of the respondents reported impairments in task efficiency, memory, emotional regulation, or organization against an expected 10% in the general population. Multivariable regression analyses independently associated impaired Neuro-QoL with hearing issues and sleep impairment among allogeneic survivors; autologous survivors' associations were similar.